Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swapnil Potdar

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Hemasphere|March 2, 2022
Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaHelena Hohtari, Matti Kankainen, Shady Adnan-Awad, et al.
Bioinformatics (Oxford, England)|March 3, 2020
Breeze: an integrated quality control and data analysis application for high-throughput drug screeningSwapnil Potdar, Aleksandr Ianevski, John-Patrick Mpindi, et al.
Clinical and Translational Medicine|January 1, 2020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatmentErlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, et al.
Cell Reports. Medicine|September 1, 2021
Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatmentsSarang S Talwelkar, Mikko I Mäyränpää, Lars Søraas, et al.
European Urology Focus|March 18, 2023
Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic TargetsSilvia Angori, Amir Banaei-Esfahani, Katharina Mühlbauer, et al.
Molecular Cancer Therapeutics|July 20, 2019
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i>-Mutant Lung CancersSarang S Talwelkar, Ashwini S Nagaraj, Jennifer R Devlin, et al.
Scientific Reports|July 21, 2021
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinomaKatja Tuomainen, Aini Hyytiäinen, Ahmed Al-Samadi, et al.
BMC Cancer|June 27, 2019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaErlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, et al.
Cell Reports. Medicine|April 23, 2024
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemiaShady Adnan Awad, Olli Dufva, Jay Klievink, et al.
Cancers|January 8, 2020
Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug TestingKatja Tuomainen, Ahmed Al-Samadi, Swapnil Potdar, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Hemasphere|March 2, 2022
Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaHelena Hohtari, Matti Kankainen, Shady Adnan-Awad, et al.
Bioinformatics (Oxford, England)|March 3, 2020
Breeze: an integrated quality control and data analysis application for high-throughput drug screeningSwapnil Potdar, Aleksandr Ianevski, John-Patrick Mpindi, et al.
Clinical and Translational Medicine|January 1, 2020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatmentErlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, et al.
Cell Reports. Medicine|September 1, 2021
Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatmentsSarang S Talwelkar, Mikko I Mäyränpää, Lars Søraas, et al.
European Urology Focus|March 18, 2023
Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic TargetsSilvia Angori, Amir Banaei-Esfahani, Katharina Mühlbauer, et al.
Molecular Cancer Therapeutics|July 20, 2019
Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i>-Mutant Lung CancersSarang S Talwelkar, Ashwini S Nagaraj, Jennifer R Devlin, et al.
Scientific Reports|July 21, 2021
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinomaKatja Tuomainen, Aini Hyytiäinen, Ahmed Al-Samadi, et al.
BMC Cancer|June 27, 2019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaErlend Skaga, Evgeny Kulesskiy, Artem Fayzullin, et al.
Cell Reports. Medicine|April 23, 2024
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemiaShady Adnan Awad, Olli Dufva, Jay Klievink, et al.
Cancers|January 8, 2020
Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug TestingKatja Tuomainen, Ahmed Al-Samadi, Swapnil Potdar, et al.
Pageof 4